{
    "nct_id": "NCT05226598",
    "official_title": "A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)",
    "inclusion_criteria": "* A histologically or cytologically confirmed diagnosis of Stage IV squamous or non-squamous NSCLC\n* Has not received prior systemic treatment for metastatic NSCLC\n* Has measurable disease based on RECIST 1.1, as determined by the local site assessment\n* Has a life expectancy of at least 3 months\n* Males: Use contraception unless confirmed to be azoospermic; Females: Women of childbearing potential use highly effective contraceptive method\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Severe hypersensitivity to MK-7684, MK-7684A, pembrolizumab, chemotherapy components, and/or any of its excipients\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study medication\n* Active autoimmune disease that has required systemic treatment in past 2 years, except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid)\n* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease\n* Has an active infection requiring systemic therapy\n* Has a known history of human immunodeficiency virus (HIV), Hepatitis B or/and Hepatitis C virus\n* Received prior systemic anticancer therapy for metastatic disease\n* Received a live or live attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed\n* History of allogeneic tissue/solid organ transplant\n* Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose â‰¤1.3 g/day, for a 5-day period (8-day period for long-acting agents, such as piroxicam)\n* Is unable or unwilling to take folic acid or vitamin B12 supplementation\n* Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention",
    "miscellaneous_criteria": "The main inclusion and exclusion criteria include but are not limited to the following:"
}